# Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors

> **NCT00499291** · NA · WITHDRAWN · sponsor: **Eastern Cooperative Oncology Group**

## Conditions studied

- Cancer

## Interventions

- **DRUG:** paclitaxel albumin-stabilized nanoparticle formulation
- **PROCEDURE:** gene expression analysis
- **PROCEDURE:** laboratory biomarker analysis
- **PROCEDURE:** pharmacological study
- **PROCEDURE:** polymerase chain reaction

## Key facts

- **NCT ID:** NCT00499291
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2023-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00499291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00499291, "Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00499291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*